Number of COVID-19 cases required in a population to detect SARS-CoV-2 RNA in wastewater in the province of Alberta, Canada: Sensitivity assessmentResearch article Published on 2023-03-012022-10-05 Journal: Journal of environmental sciences (China) [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] analysis Analysis collected Community COVID-19 COVID-19 case COVID-19 cases Critical dataset defined detect detection rate Detection sensitivity Epidemiology Estimated IMPROVE input median negative test number plant positive prevalence of COVID-19 Probability Probit analysis provided required RT-qPCR SARS-CoV-2 SARS-CoV-2 RNA SARS-CoV-2 RNA detection sensitivity study period Support Surveillance threshold Treatment unique wastewater [DOI] 10.1016/j.jes.2022.04.047 [Article Type] Research article
Assessing the reporting quality of randomized controlled trials on COVID-19 vaccines: a systematic reviewCOVID-19 백신에 대한 무작위 대조 시험의 보고 품질 평가: 체계적인 검토Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] 임상, [키워드] adverse effect Analysis analysis of variance Assessing CONSORT CONSORT statement controlled trials COVID-19 COVID-19 vaccine COVID-19 vaccines criteria current database effective evaluated Evidence groups independent indicate indicated median Mortality no significant difference predicted Randomized Randomized controlled trial Randomized controlled trials RCT RCTs reported Reporting Reporting quality review. Standard systematic review Univariate analysis variance variety [DOI] 10.1080/21645515.2022.2031453 PMC 바로가기 [Article Type] Article
Dynamics of viral shedding during ancestral or Omicron BA.1 SARS-CoV-2 infection and enhancement of pre-existing immunity during breakthrough infectionsArticle Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] addition Anti-RBD IgG antibody Breakthrough infection Cell cellular immunity cellular response circulating Delta Diagnosis Dynamics exhibited faster greater HCW HCWs healthcare worker humoral IFN-γ Immunity Infection infectiousness investigated isolates median neutralization capacity neutralizing antibody titre normalized omicron pandemic positive pre-existing immunity proportion reported RT-qPCR SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 isolates SARS-CoV-2 peptides SARS-CoV-2 variants symptom onset Vaccine vaccine-immunity variant viral clearance viral culture Viral load viral loads viral shedding Viral shedding. [DOI] 10.1080/22221751.2022.2122578 PMC 바로가기
Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control studyArticle Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 치료기술, 치료제, [키워드] 95% CI adjusted hazard ratio Antiviral antiviral. ARMS clinical clinical condition Clinical improvement complications control arm COVID-19 COVID-19 patient Day defined early treatment Effect Efficacy enrolled enrolment faster Favipiravir female FPV investigated likelihood median median time mild case mild pneumonia multicentre Patient PCR-confirmed Pneumonia primary endpoint randomized control study RdRP RdRp inhibitor registry risk of COVID-19 SARS-CoV-2-infected patient score significantly higher supportive care sustained symptomatic Thailand Treatment viral clearance Viral detection [DOI] 10.1080/22221751.2022.2117092 PMC 바로가기
COVID-19 and the injured patient: A multicenter reviewResearch article Published on 2022-12-012022-10-05 Journal: The Journal of surgical research [Category] 바이오마커, [키워드] adverse events Affect age Analysis baseline characteristics C-reactive protein Coagulopathy Cohort collected Comorbidities composed Coronavirus disease 2019 COVID-19 cumulative D-dimer demographics diabetes events ferritin Frame Hospitalization hypertension In-hospital death Injury ISS Kaplan–Meier method log-rank test median morbidity and mortality Mortality multicenter neurologic New York Older outcome outcomes Patient patients performed physiological Primary outcome Result Retrospective analysis severity shown study period surgical tested trauma trauma patient trauma patients were excluded were used [DOI] 10.1016/j.jss.2022.06.068 [Article Type] Research article
SARS-CoV-2 RNA load in nasopharyngeal specimens from outpatients with breakthrough COVID-19 due to Omicron BA.1 and BA.2Article Published on 2022-12-012022-11-16 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, [키워드] acute respiratory syndrome All participant BA.1 BA.2 Booster vaccine caused collected comparable composed coronavirus coronavirus disease COVID-19 Day Diagnosis dose elapsed had no Infection log median median age nasopharyngeal specimen omicron Omicron variant Outpatient Patient reached retrospective RNA SARS-CoV-2 SARS-CoV-2 RNA Support symptom onset TaqPath Thermo Fisher Scientific time Transmissibility upper respiratory tract URT vaccination schedule Vaccine vaccine dose Viral load Viral load. viral RNA load was used [DOI] 10.1002/jmv.28079 PMC 바로가기
Influenza and pneumococcal vaccination and COVID-19 in kidney transplant patientsResearch article Published on 2022-12-012022-10-05 Journal: Transplant immunology [Category] 변종, 진단, 치료제, [키워드] addition administration benefit Clinical course control group COVID COVID-19 COVID-19 infection disease Donor dysfunction examined follow-up time group Hospital stay Hospitalization increased the risk Influenza Influenza and pneumoccal vaccine intensive care kidney transplant kidney transplant recipient lack Logistic regression analysis median multivariate need for dialysis no significant difference observation outcome pandemic Patient pneumococcal positive recipient reduce Result risk of COVID-19 rRT-PCR test significantly higher the disease the patient vaccination vaccination rate Vaccine Vaccines with COVID-19 [DOI] 10.1016/j.trim.2022.101693 [Article Type] Research article
Humoral responses after inactivated COVID-19 vaccination in individuals with and without prior SARS-CoV-2 infection: A prospective cohort studyArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] acute respiratory syndrome antibody asymptomatic infections benefit blood sample booster dose Clinical severity collected coronavirus coronavirus disease COVID-19 COVID-19 vaccination detectable dose evaluated Evidence first dose humoral humoral immune response Humoral immunity Humoral response inactivated Inactivated COVID-19 vaccine individual individuals infected individuals Infection median mild cases moderate multicenter NAb titer NAbs naïve individual naïve individuals natural infection Neutralizing Neutralizing activity neutralizing antibody omicron pan-immunoglobulins. participant prospective cohort study Protein receive recovered patient SARS-CoV-2 second dose seroconversion rate severity significantly single dose single vaccine the vaccine U/mL vaccination variant [DOI] 10.1002/jmv.28055 PMC 바로가기
Combination therapy with remdesivir and immunomodulators improves respiratory status in COVID-19: A retrospective studyArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 치료제, [키워드] 95% confidence interval Analysis Baricitinib baseline benefit body mass index combination therapy Concomitant contributed control group coronavirus disease COVID-19 COVID-19 patient COVID-19 patients Day Diabetes Mellitus examined faster greater hazard ratio immunomodulator immunomodulators IMPROVE in both group independent investigated median outcome Oxygen administration Patient patients Prognostic factors Remdesivir respiratory recovery retrospective Retrospective study severity single-center study standard treatment supplemental oxygen survival synergistic therapy Tocilizumab tocilizumab. treated two group [DOI] 10.1002/jmv.28037 PMC 바로가기
SARS-CoV-2 vaccine booster in solid organ transplant recipients previously immunised with inactivated versus mRNA vaccines: A prospective cohort studyArticle Published on 2022-12-012022-10-06 Journal: Lancet Reg Health Am [Category] 진단, [키워드] age All participant anti-SARS-CoV-2 BNT162b2 BNT162b2 vaccine booster Care cohort study CoronaVac COVID-19 determine dose effective end point General population groups Heterologous heterologous vaccine homologous humoral immune response IFN-γ IgG antibody IL-2 inactivated kidney liver median Medicine more difficult mRNA mRNA vaccine neutralising antibody not differ of BNT162b2 outcome Patient priming proportion Prospective prospective cohort study recipient recipients Red SARS-CoV-2 SARS-CoV-2 vaccine School secondary secreting significantly significantly higher solid organ solid organ transplant SOT T-cell T-cell responses vaccination Vaccine vaccine immunogenicity. women [DOI] 10.1016/j.lana.2022.100371 PMC 바로가기 [Article Type] Article